18 news items
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
IVVD
31 May 24
SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
IVVD
31 May 24
targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
IVVD
24 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
IVVD
14 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
IVVD
7 May 24
targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein have been highly effective therapeutic options for symptomatic COVID-19
omnn2
IVVD
15 Apr 24
in target population WALTHAM, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc
yerrd8lhuk7g4et 08cnq38nvjup7zu
IVVD
12 Apr 24
according to estimates from the Centers for Disease Control and Prevention. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD
xgr kydb4g8ltihetupw2t
IVVD
5 Apr 24
Guggenheim analyst Evan Wang upgrades Invivyd (NASDAQ:IVVD) from Neutral to Buy and announces $9 price target.
fyuj2v3h
CNK
CRBU
DNUT
5 Apr 24
Neutral to Overweight and raised its price target from $14 to $20.
Forge Global Holdings, Inc
s38mp8b2fx3f2ydcd9 dwk6ez3mm1btye8ardeu821agxtu3hzy5f
IVVD
4 Apr 24
according to estimates from the Centers for Disease Control and Prevention. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD
bkjhnz2qqewbecq6qyu605z6b0thi
AHG
AKBA
APCX
26 Mar 24
to Overweight and raised the price target from $4 to $10.
Sunnova Energy International Inc
vzk vdnfzi85okhuns8
APPF
CGC
DNUT
26 Mar 24
to Overweight and raised its price target from $4 to $10.
Qurate Retail Inc
0xonlknrl1jatpcgaww7c9h hryg
APCX
BREA
BZFD
26 Mar 24
. Morgan Stanley analyst Maxwell Skor upgraded Invivyd from Equal-Weight to Overweight and raised the price target from $4 to $10
2mfqp0k9a5o5kd9hbx0rk0c71rec gq9exq
IVVD
26 Mar 24
Morgan Stanley analyst Maxwell Skor upgrades Invivyd (NASDAQ:IVVD) from Equal-Weight to Overweight and raises the price target from $4 to $10.
30lo6y0hm8dntx7crm3l
ABBV
AEHR
AKAN
25 Mar 24
offering.
Target Hospitality Corp. (NASDAQ:TH) jumped 21.3
jmx zs0oh
IVVD
25 Mar 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
2vizmlhff
IVVD
22 Mar 24
targeting conserved epitopes that could be deployed to keep pace with SARS-CoV-2 viral evolution or other viral threats. With a commitment to serial
44wnf5468xjv x18u
IVVD
22 Mar 24
is designed to enable the rapid, serial generation of durable mAbs targeting conserved epitopes that could be deployed to keep pace with SARS-CoV-2 viral
- Prev
- 1
- Next